REF-376 · Hull, Wootten et al., 2022 / Halle et al., 2021 (post-COVID / illness return) · British Journal of Sports Medicine, · Paper
COVID-19 in UK international athletes: mostly mild and self-limiting, but median time loss 18 days and 27% still unavailable after 4 weeks
Lower-respiratory features triple the risk of prolonged illness
Participants
n=147 UK elite athletes with symptomatic COVID-19 managed within the UK Sports Institutes, 24 February 2020 – 18 January 2021; 25 Paralympic (17%); mean age 24.7 (SD 5.2) years; 37% female; 71 confirmed (PCR or antibody), 76 probable (consistent clinical features).
Protocol
Observational, clinical and database review; presentation classified by predominant symptom focus (upper vs lower respiratory)
Time loss = days unavailable for full sport participation
Comparator: 2016-2019 non-COVID respiratory illness dataset from the same surveillance system
Key Results
Symptoms: fatigue most prevalent (57%), then dry cough (50%) and headache (46%)
Symptom duration: median 10 days (IQR 6-17); 14% had symptoms >28 days
Time loss: median 18 days (IQR 12-30); 27% not fully available >28 days from initial infection date
vs historical non-COVID respiratory illness: median time loss 6 days (0-7), p<0.001; 4% unavailable at 28 days
Lower-respiratory phenotype (dyspnoea ± chest pain ± cough ± fever) in 18%: relative risk of prolonged symptoms 3.0 (95% CI 1.4-6.5) and of time loss 2.1 (95% CI 1.2-3.5)
Authors' conclusion: COVID-19 was largely a mild, self-limiting illness in this cohort, but lower respiratory tract features were associated with prolonged illness and delayed return to sport
Practical Application
In n=147 UK international athletes with symptomatic COVID-19, the illness was mostly mild and self-limiting, yet median time loss was 18 days (vs 6 days for ordinary respiratory illness) and 27% were still not fully available after 4 weeks; athletes with lower-respiratory features (breathlessness, chest pain, cough, fever — 18% of the cohort) had 3× the risk of prolonged symptoms and 2× the risk of prolonged time loss — plan a post-COVID return in weeks, not days, and treat chest symptoms as the marker that lengthens it.
Lower-respiratory features are the triage signal in this cohort: an athlete with breathlessness, chest pain or fever belongs on the slow track and, per cardiac return-to-play guidance (ACC / AMSSM, Halle 2021 — not this paper), should be medically assessed before hard training.
Median time loss across the cohort was 18 days even though most cases were mild — do not read "mild" as "back in a week".
Underestimate, don't overestimate return capacity — one athlete in four in this elite, medically supervised cohort was still not fully available at 4 weeks.
Not from this paper — general return-to-play guidance
The cohort above measured illness pattern and time loss; it did not test any return protocol. The guidance below comes from a separate return-to-play consensus and from general sports-medicine practice, not from this cohort, and is not checked against any abstract.
"Neck-up" rule: symptoms only above the neck (runny nose, mild sore throat, no fever) → light exercise may be OK; "neck-down" / systemic symptoms (fever, body aches, chest symptoms, GI) → rest until symptom-free plus 24-48 h; no hard training within about 7 days of fever resolution
COVID-19 severity tiers (ACC / AMSSM-type guidance): asymptomatic/mild → graduated return after symptom resolution over 2-4 weeks; moderate (prolonged symptoms, pulmonary involvement) → cardiac screening (ECG, troponin, echo if indicated) before return, phased return over 4-8 weeks; severe/hospitalised → full cardiac work-up before return, multi-month phased return; myocarditis screening critical
Long-COVID / post-viral fatigue: pacing approach (symptom-titrated), avoid push-through
Graduated return framework (5-stage; separate return-to-play consensus, not this cohort): (1) rest and minimal activity until symptoms resolve; (2) light aerobic 10-15 min, <70% HRmax, 2+ days; (3) moderate aerobic + mobility 15-30 min, <80% HRmax, 2+ days; (4) complex/skill training ~60 min near-normal intensity, 2+ days; (5) full training. Progress only symptom-free with a normal HR response; drop back 1-2 stages if symptoms recur.
Monitor HRV / morning HR during return — elevated HR at easy intensity = not ready; any chest pain, breathlessness or palpitations during return → medical evaluation before proceeding
Limitations
Observational cohort of elite UK athletes in 2020-21 (pre-vaccination, early variants); COVID-specific guidance evolves quickly — check current literature
76 of 147 cases were "probable" (clinical features), not laboratory-confirmed
Time loss reflects medically supervised institute practice, which may be more conservative than self-managed amateurs
Cardiac screening thresholds vary by institution/country; long-COVID management is an active research area with patchy evidence
Individual variation in recovery kinetics large
How this entry was checked and changed
Why this level
regraded 2026-09-27 from B+: observational cohort, n=147; the return-to-play framework in this entry is carried from a separate consensus, not from this cohort
Content correction 2026-09-27
Entry carried none of the cohort's findings -> added: n=147 elite athletes, median symptoms 10 d, median time loss 18 d (vs 6 d non-COVID), 27% unavailable >28 d, lower-respiratory phenotype RR 3.0 for prolonged symptoms and 2.1 for time loss.
The 5-stage graduated return framework, neck rule and severity tiers -> credited to a separate return-to-play consensus / ACC-AMSSM guidance, not this cohort; "miss a week → 2-week return" default removed.
Body cited DOI 10.1136/bjsports-2020-103638 for Hull 2022 -> the entry's own head DOI 10.1136/bjsports-2021-104392 is the cohort paper; the other identifier is not this paper. Level B+ -> B (cohort, n=147); Tier -> 4.
Second pass 2026-09-27 (number-by-number check against the abstract): "upper-respiratory only: median 2.5 weeks" is not in the abstract -> replaced by the cohort median time loss (18 days), which is.